B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent ...
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed ...
Four principles for getting AI agents past the pilot phase in regulated pharma manufacturing. AI agents are the latest technology that organizations are adopting at enterprise scale after finding ...
J&J’s separations of Kenvue and DePuy Synthes test whether Innovative Medicine and MedTech create more value together than ...
As specialty drug complexity grows, agentic technology puts the right access, adherence, and affordability resources at the ...
Dr. Joe Geraci of NetraMark explains how AI analysis of clinical trial data can uncover hidden responder subgroups, separate ...
DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics ...
Parexel’s Stacy Hurt explains why AI can speed up clinical research but can’t replace the lived experience of patients.
With rising healthcare costs, practices are embracing flexible payment models and upfront pricing transparency to keep care accessible.
The White House has withdrawn Dr. Heidi Overton’s nomination for FDA commissioner just a day before a Senate committee vote.
Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.